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Abstract
A common and histologically well defined subtype of glioma are the oligodendroglial brain tumors. Approximately 70% of
all oligodendrogliomas have a combined loss of the entire 1p and 19q chromosomal arms. This remarkably high frequency
suggests that the remaining arms harbor yet to be identified tumor suppressor genes. Identification of these causal genetic
changes in oligodendrogliomas is important because they form direct targets for treatment. In this study we therefore
performed targeted resequencing of all exons, microRNAs, splice sites and promoter regions residing on 1p and 19q on 7
oligodendrogliomas and 4 matched controls. Only one missense mutation was identified in a single sample in the ARHGEF16
gene. This mutation lies within- and disrupts the conserved PDZ binding domain. No similar ARHGEF16 mutations or
deletions were found in a larger set of oligodendrogliomas. The absence of common somatic changes within genes located
on 1p and 19q in three out of four samples indicates that no additional ‘‘second hit’’ is required to drive oncogenic
transformation on either chromosomal arm.
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Introduction
A common and histologically well defined subtype of glioma are
the oligodendroglial brain tumors. Oligodendrogliomas differ from
the other glioma subtypes in clinical behavior with respect to
overall prognosis (median survival 3 years versus less than one
year) and a relatively better and longer lived response to
chemotherapy and radiotherapy [1–3]. Oligodendrogliomas have
clearly distinct gene expression profiles [4–6] and are also
cytogenetically distinct: approximately 70% of all oligodendrogli-
omas have a combined loss of the entire short arm of chromosome
1 (1p) and loss of the entire long arm of chromosome 19 (19q)
[1,3–5,7]. Loss of these chromosomal arms in oligodendrogliomas
is highly correlated with chemosensitivity; approximately 80–90%
of oligodendroglial tumors with LOH (loss of heterozygosity) on 1p
and 19q respond to chemotherapy [1,2,8]. Conversely only 25–
30% of tumors that have retained the short arm of chromosome
1p are sensitive to chemotherapy. In summary, oligdendrogliomas
are a clinically, histologically, cytogenetically and molecularly
distinct and well defined subgroup of glioma.
In spite of these clearly distinct clinical, histological and
molecular features, little is known on the genetic changes that
drive these tumors. Thusfar, IDH1/IDH2 (70%) and, to a much
lesser extent, TP53 (15–25%) and PIK3CA (10–15%) are the only
genes that are mutated at significant frequency in this tumor type
[9–15]. The remarkably high frequency of LOH of 1p and 19q
suggests the remaining arms harbor yet to be identified tumor
suppressor genes (Knudson two-hit hypothesis [16]). Identification
of the causal genetic changes is important because they form direct
targets for treatment: Tumor growth depends on these acquired-
somatic- changes both in oncogenes (‘‘oncogene addiction’’ [17])
and in tumor suppressor genes [18,19]. In this study we therefore
aimed to identify genetic changes in all exons, microRNAs, splice
sites and promoter regions on 1p or 19q using array capture and
Next Generation Sequencing. Experiments were performed on 7
oligodendrogliomas and 4 had matched control DNA samples.
Materials and Methods
Glioma samples were collected from the Erasmus MC tumor
archive. Samples were collected immediately after surgical resection,
snap frozen, and stored at 280uC. The use of patient material was
approved of by the Institutional Review Board of the Erasmus MC,
Rotterdam, the Netherlands (nr MEC 221.520/2002/262; date of
approval July 22, 2003, and MEC-2005-057, date of approval
February 14, 2005). For this use, patients gave written informed
consent according to institutional and national guidelines.
All oligodendrogliomas used (n=7) had proven loss of 1p and
19q as assessed by SNP 6.0 or 250 k NspI arrays (both Affymetrix,
Santa Clara, USA) [7] and highly similar RNA expression profiles
(i.e. belong to the same molecular subgroup) [6]. Control DNA
was available in 4/7 cases. The candidate variations of 4 samples
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22000were used for validation experiments. By using 4 samples we have
a 76.0% chance of identifying each mutation with a frequency of
30%. DNA was amplified using a Repli-G midi kit (Qiagen,
Venlo, the Netherlands) to ensure sufficient DNA amounts.
Patient characteristics are listed in table 1.
Capture arrays (Nimblegen, Roche NimbleGen, Inc., Waldk-
raiburg, Germany) were designed to enrich for all exons, miRNAs,
splice sites (defined as 10 bp up- or downstream of a coding exon)
and promoter regions (defined as 100 bp upstream of a transcript)
of transcripts present in Refseq, Ensembl or Vega based on the
NCBI36/hg18 build. Two capture arrays were designed covering
around 5 million bp of sequence each. We were able to design
capture probes for 96.0% and 94.4% of all regions on chr 1 and
chr 19 respectively, remaining sequences contained non unique
sequences (.5 fold presence in the human genome). Amplified
DNA samples were fragmented by sonication, end repaired and
ligated to paired end adaptors. Samples were size selected
(300 bp), enriched for 1p and 19q by array capture, PCR-
amplified and 76 bp paired end sequenced using the Illumina
GA2x sequencer. The Illumine Casava pipeline was used for base
calling and quality control.
The CLC Bio Genomics Workbench (Aarhus, Denmark) was
used to align sequence reads against the reference genome. All the
experiments were successful except for one of the two capture
arrays of sample 229, which was omitted from the analysis. We
defined reads subject for mutational analysis as being covered at
least 7 times in the tumor sample and at least 8 times in the
matching control sample. This coverage was set deliberately low
(often $30 fold coverage is used) and was aimed to include as
many evaluable targeted regions as possible.
Single Nucleotide Variants (SNVs) and Deletion or Insertion
Variants (DIVs) were detected by the CLC Bio Genomic
Workbench and filtered using the following criteria (coverage of
at least 7 (tumor) or 8 (ctr), variant frequency at least 70% (tumor)
or 30% (controls). The difference in variant frequency between
tumors and normals is because only homozygous changes are
expected in the tumor (because of the 1p19q LOH). To allow for
tumor heterogeneity (presence of non-neoplastic tissue) and
stochastic effects (allele specific sequencing) these percentages
were set lower than 100% and 50%.
Results
The mean total number of matched bp sequenced per sample
was 2.89 billion (1.17 billion in sample 229). Of these, 73.5% was
on our targeted regions (range 70.4–84.8%, one outlier at 41.3%)
confirming capture efficiency. The coverage of our targeted
regions was at least 7 in 96.5% of our target regions (range 87.6–
98.9) (see also figure 1). Coverage of genes suggested to be involved
in (oligodendro-) glioma genesis CAMTA1 [20], EMP3 [21],
CHD5 [22], DIRAS3 [23] and PLA2G4C [24] is listed in table 2.
We first calculated the tumor percentage of all samples. The
tumor content can be estimated by the observed B allele frequency
of SNPs using tumor samples only. For example, in case of 50%
tumor, the observed B allele frequency would amount to 66.7% (in
case of LOH in the tumor). In our sample cohort, the observed B
allele frequency was 91.2–97.3% (except for sample 11 with an
observed frequency of 85.0%), corresponding to 90.3–97.2%
tumor (82.4% for sample 11). A tumor content $82.4% indicates
that a mutant allele frequency of 70% (corresponding to a tumor
percentage of 82.4%) is a suitable value as detection cutoff for the
mutant allele frequency.
We then prioritized all changes identified based on their
associated function into: tier 1 (coding exons, splice sites and
miRNAs), tier 2 (promoters and UTRs), tier 3 (intronic regions)
and tier 4 (SNPs and personal SNPs). In tiers 1, 2, 3 and 4 we
identified 431, 1380, 16293 and 72466 SNVs and DIVs
respectively. A high number of all variants present in tier 4 were
not present in dbSNP130, and are likely to reflect personal SNPs
and sequencing artefacts (see also table 3). We then performed
direct sequencing on all tier 1 candidates and all candidates within
promoter regions (part of tier 2). 505 of the 514 sequence reactions
were successful; only 2/9 unsuccessful candidates were predicted
to result in a change in the primary protein sequence (both
missense mutations).
Of the 514 candidate variants 77% (n=394) were not confirmed
on tumor DNA using direct sequencing (false positive). Such variants
likely represent amplification artefacts (due to e.g. whole genome
amplification or the post capture PCR amplification) and/or
sequencing artefacts (e.g. sequencing errors). A further 21%
(n=110) could be confirmed in the tumor samples, but the variant
was also present in the matched control DNA. These variants may
represent selective allele amplification and sequencing. In summary,
of the 514 candidates subject to direct sequencing, one variant was
validated. This variant is a missense mutation (c.2125 G.A)
(figure 2a) and affects the last amino acid (p.V709M) of ARHGEF16
(RefSeq: NM_014448.3) in sample 8. It should be noted that the
absence of trace wt sequence in the chromatogram confirms the high
tumor percentage in this sample. The base is highly conserved
(GERP conservation score 3.35 [25]. This amino acid is located
Table 1. Patient characteristics of all tumor samples.
Sample Gender Diagnosis Age KPS Surgery RT CT Alive Surv (years)
8 F OD III 44 100 PR yes no Dead 9.82
11 M OD III 38 CR yes no Dead 8.92
13 M OD III 33 90 PR Dead 8.59
21 M OD III 31 100 PR yes no Dead 6.81
23 F OD III 44 90 CR yes no Dead 8.12
229 M OA III 35 90 CR yes Adj PCV Alive 6.8
538 F OD II 44 80 SB Alive 3.27
OD = oligodendroglioma, OA = oligoastrocytoma, KPS = Karnofsky performance score,
PCV = procarbazine, lomustine, vincristine.
F= female, M= male, OD = oligodendroglioma, OA = oligoastrocytoma, grades II or III. Age= age at diagnosis. KPS = Karnofsky performance score, PCV =
procarbazine, lomustine, vincristine. Surgery types: PR= partial resection, CR= complete resection, SB= stereotactic biopsy. RT= radiotherapy, CT= Chemotherapy.
doi:10.1371/journal.pone.0022000.t001
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domain). However, it remains to be determined whether the
identified mutation affects its RhoA guanine exchange function and
oncogenic transformation potential [26].
None of the other 6 samples contained changes in the coding
sequence of ARHGEF16. In addition, we failed to identify
mutations in the last exon of ARHGEF16 in an additional 32
samples from the same molecular cluster [6] using direct
sequencing. No small homozygous deletions were identified on
SNP 6.0 and 250 k Nsp arrays from 23 oligodendrogliomas [7].
The ARHGEF16 promoter does show hypermethylation on
Infinium Methylation arrays (Illumina, San Diego, USA), on 68
anaplastic oligodendrogliomas and oligoastrocytomas; PF, manu-
script in prep) and is correlated with loss of 1p and 19q (p=0.035,
Fisher exact test). Data are listed in table 4. In addition, tumors
with hypermethylated ARHGEF16 promoter have a better
survival (5.62 years versus 1.31 years; p,0.0001) (figure 2b).
Promoter methylation of ARHGEF16 may therefore be involved
in the formation of gliomas with loss of 1p and 19q.
Discussion
We have systematically sequenced all exons, miRNAs, splice sites
and promoter regions on 1p and 19q. Of the 514 candidate variants
in coding exons, miRNAs, splice sites and promoter regions, onlyone
was validated: a missense mutation in ARHGEF16 affecting the
PDZ-binding domain. ARHGEF16 lies on 1p36 a region that is
commonly deleted in gliomas [20,22,27]. However, no other genetic
changes were detected in the ARHGEF16 gene in a panel of 32
additional oligodendrogliomas, though the promoter is frequently
hypermethylated. Future experiments should determine whether this
specific mutation contributes to the pathogenesis of the disease.
In our sample cohort, only one somatic mutation in a single
sample was identified among the ,10
7 bases of sequence evaluated.
The overall mutation rate in oligodendrogliomas therefore is at least
an order of magnitude lower than reported for many other cancer
types including glioblastomas [12,28,29]. Recent reports however,
have highlighted tumor types that also have a very low somatic
mutation rate [30,31].
Figure 1. Coverage plot of all samples. Depicted is the percentage of targeted bases (y-axis) that is covered at least n times (x-axis) per sample.
doi:10.1371/journal.pone.0022000.g001
Table 2. Per base coverage of known candidate genes in
oligodendrogliomas located on 1p or 19q.
Sample CAMTA CHD5 DIRAS3 PLA2G4C EMP3
8 cov 200.1 264.4 107.2 32.3 57.0
min 05 2 6 2 1 5
max 896 1198 186 87 131
% covered 96.2 99.6 100 93.1 100
11 cov 58.6 20.2 127.0 79.0 90.2
min 00 1 2 7 3 3
max 275 107 231 214 183
% covered 93.5 82.1 100 100 100
13 cov 184.6 135.8 98.5 183.8 343.1
min 0 0 14 24 126
max 562 677 178 447 625
% covered 98.2 94.0 100 100 100
21 cov 163.8 77.7 208.1 202.8 281.3
min 0 2 24 50 95
max 527 329 360 449 599
% covered 96.8 98.9 100 100 100
23 cov 178.8 69.0 245.8 189.4 202.3
min 0 0 35 21 70
max 531 353 468 487 374
% covered 95.9 89.9 100 100 100
Min/Max: lowest/highest coverage, % covered: the percentage of bases
sequenced at least 7 times (the cutoff used for our analysis).
doi:10.1371/journal.pone.0022000.t002
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SNVs tier 1 tier 2 tier 3 tier 4
sample array chr exons miRNA spl site prom UTRs introns SNVs dbSNP personal SNVs
8 1 1 13 0 4 9 96 97 4312 1577
2 1 33 0 3 3 218 38 1020 841
2 19 19 0 0 6 37 23 1350 1120
11 1 1 80 0 3 4 110 68 3342 852
2 1 14 0 2 5 110 204 1787 3400
2 19 108 0 1 3 59 369 2703 4146
21 1 1 17 0 2 4 92 891 4450 1095
2 1 13 0 0 7 94 3166 2110 7892
2 19 25 0 0 4 63 3887 3090 9028
229 2 1 20 0 3 9 144 3505 146 3887
2 19 44 0 2 5 135 3543 287 13213
DIVs tier 1 tier 2 tier 3 tier 4
sample array chr exons miRNA spl site prom UTRs introns DIVs dbSNP personal DIVs
8 1 1 0 0 10 11 60 79 179 0
21 00 2163 1 8 0
2 1 9 1 00 1 9 75 4 0
11 11 00 662 7 5 11 1 8 1
21 00 0010 1 0
2 1 9 0 00 0 0 00 0
21 11 00 0000 0 0
21 00 0001 0 0
2 1 9 0 00 0 0 00 0
229 2 1 2 0 0 5 24 134 181 28
2 19 3 0 1 0 12 227 177 61
UTR= untranslated region, SNV= single nucleotide variation, DIV= deletion/insertion variation, chr=chromosome, array= capture array, spl site= splice site,
prom=promoter.
doi:10.1371/journal.pone.0022000.t003
Figure 2. ARHGEF16 (RefSeq: NM_014448.3) mutation and promoter methylation. A; Upper lane: part of the sequence of ARHGEF16 with
the missense mutation (2125G-.A) in tumor sample 8. Lower lane: sequence of the same region of ARHGEF16 in the matching control DNA. B;
Kaplan Meier survival curve of oligodendrogliomas (n=39) and oligoastrocytomas (n=11) with unmethylated ARHGEF16 (, median) (black line) or
methylated ARHGEF16 (. median) (grey line). **=p,0.01.
doi:10.1371/journal.pone.0022000.g002
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of the four samples examined no genomic second hit was found in
any of the screened regions. Our data therefore indicate that no
additional ‘‘second hit’’ is required on these chromosomal arms to
drive oncogenic transformation. It is possible that a second hit is
present on the remaining alleles but has escaped detection (e.g. due
to a skewed distribution in sequencing of the non-neoplastic alleles
derived from ‘‘contaminating’’ normal tissue) or is located in
regions not captured or covered by our capture array. Alterna-
tively, promoter methylation and/or haploinsufficiency of one or
more genes could drive oncogenesis in oligodendrogliomas with
loss of 1p and 19q. In line with this hypothesis is the high
frequency of IDH1 mutations in oligodendrogliomas with 1p and
19q LOH (see e.g. [32]) and the observation that IDH1 mutations
induce chromatin remodeling and promoter hypermethylation
[33,34]. IDH1 mutations are associated with the CpG island
hypermethylation phenotype (MvdB and PF, submitted), and
promoter hypermethylation in cancer often occurs in the promoter
regions of tumor suppressor genes [35,36]. Promoter hypermethy-
lation of tumor suppressor genes in combination with somatic
mutations in a limited number of genes therefore may drive
oncogenesis in oligodendrogliomas with 1p and 19q LOH.
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Table 4. Percentage methylation of two different CpG sites (cg24919884 and cg02737335) within the ARHGEF16 locus.
ARHGEF16
Sample cg24919884 cg02737335 survival censoring Sample cg24919884 cg02737335 survival censoring
1 0.767 0.69 1.104 1 42 0.874 0.817 1.633 1
10 0.642 0.754 1.071 1 43 0.691 0.794 1.208 1
11 0.777 0.829 4.008 0 44 0.788 0.739 1.063 1
12 0.657 0.285 3.408 0 45 0.879 0.845 7.734 0
13 0.251 0.313 2.548 1 47 0.565 0.663 1.31 1
14 0.828 0.831 0.775 1 48 0.81 0.821 0.523 1
15 0.773 0.771 0.326 1 49 0.876 0.84 5.003 1
16 0.565 0.737 1.663 1 5 0.617 0.813 2.732 1
17 0.867 0.872 3.54 1 50 0.623 0.8 0.195 1
18 0.487 0.609 1.416 1 51 0.866 0.802 5.814 1
19 0.706 0.688 0.819 1 52 0.855 0.834 8.227 0
20 0.681 0.688 1.625 1 53 0.862 0.835 2.997 1
21 0.851 0.823 2.485 1 54 0.439 0.469 1.34 1
22 0.878 0.829 2.627 0 55 0.879 0.824 8.036 1
23 0.835 0.822 0.625 1 56 0.852 0.831 8.233 0
24 0.857 0.849 5.827 0 57 0.704 0.4 0.707 1
25 0.412 0.729 1.625 1 58 0.836 0.778 0.975 1
26 0.615 0.646 1.447 1 59 0.846 0.824 2.022 1
27 0.821 0.854 6.17 0 6 0.503 0.468 1.014 1
28 0.773 0.818 1.236 1 60 0.856 0.85 3.038 1
29 0.635 0.712 0.548 1 62 0.817 0.819 0.997 0
3 0.888 0.861 1.222 1 63 0.882 0.83 6.992 0
30 0.883 0.874 4.26 1 64 0.803 0.758 0.258 1
31 0.439 0.635 1.134 1 65 0.88 0.854 5.019 1
32 0.851 0.811 3.488 0 66 0.819 0.798 3.304 1
33 0.415 0.53 4.849 0 67 0.527 0.752 0.537 1
34 0.858 0.826 3.488 0 68 0.884 0.844 5.622 1
35 0.882 0.857 6.874 0 69 0.847 0.813 15.819 1
36 0.853 0.802 0.348 1 7 0.494 0.692 1.616 1
37 0.866 0.83 6.71 0 70 0.843 0.841 18.715 1
39 0.839 0.809 2.836 1 73 0.465 0.631 3.652 1
4 0.909 0.815 6.31 0 74 0.723 0.625 1.175 1
40 0.413 0.63 7.526 1 8 0.307 0.715 1.345 1
41 0.834 0.721 3.795 1 9 0.835 0.817 2.038 1
Values correspond to the fraction of methylation (scale 0–1).
doi:10.1371/journal.pone.0022000.t004
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